Fayez Sarofim & Co’s Idexx Laboratories IDXX Stock Holding History

Fayez Sarofim & Co’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Sell	2,054 -150	-7%	-$84.1K	﹤0.01%	182
2026 Q1	$1.24M	Sell	2,204 -200	-8%	-$128K	﹤0.01%	172
2025 Q4	$1.63M	Hold	2,404	–	–	﹤0.01%	164
2025 Q3	$1.54M	Hold	2,404	–	–	﹤0.01%	171
2025 Q2	$1.29M	Hold	2,404	–	–	﹤0.01%	180
2025 Q1	$1.01M	Sell	2,404 -125	-5%	-$54.3K	﹤0.01%	188
2024 Q4	$1.05M	Sell	2,529 -100	-4%	-$43.9K	﹤0.01%	182
2024 Q3	$1.33M	Hold	2,629	–	–	﹤0.01%	162
2024 Q2	$1.28M	Buy	2,629 +200	+8%	+$100K	﹤0.01%	161
2024 Q1	$1.31M	Buy	2,429 +200	+9%	+$109K	﹤0.01%	157
2023 Q4	$1.28M	Buy	2,229 +650	+41%	+$305K	﹤0.01%	152
2023 Q3	$690K	Sell	1,579 -100	-6%	-$49.9K	﹤0.01%	186
2023 Q2	$843K	Hold	1,679	–	–	﹤0.01%	174
2023 Q1	$840K	Sell	1,679 -112	-6%	-$53.6K	﹤0.01%	184
2022 Q4	$731K	Hold	1,791	–	–	﹤0.01%	190
2022 Q3	$584K	Buy	1,791 +175	+11%	+$64.3K	﹤0.01%	207
2022 Q2	$567K	Sell	1,616 -138	-8%	-$56.3K	﹤0.01%	219
2022 Q1	$960K	Hold	1,754	–	–	﹤0.01%	204
2021 Q4	$1.16M	Hold	1,754	–	–	﹤0.01%	198
2021 Q3	$1.09M	Hold	1,754	–	–	﹤0.01%	187
2021 Q2	$1.11M	Hold	1,754	–	–	﹤0.01%	193
2021 Q1	$858K	Hold	1,754	–	–	﹤0.01%	188
2020 Q4	$877K	Hold	1,754	–	–	﹤0.01%	177
2020 Q3	$690K	Sell	1,754 -188	-10%	-$69.5K	﹤0.01%	175
2020 Q2	$641K	Hold	1,942	–	–	﹤0.01%	177
2020 Q1	$470K	Sell	1,942 -100	-5%	-$26.1K	﹤0.01%	181
2019 Q4	$533K	Buy	2,042 +100	+5%	+$26.4K	﹤0.01%	200
2019 Q3	$528K	Hold	1,942	–	–	﹤0.01%	192
2019 Q2	$535K	Hold	1,942	–	–	﹤0.01%	186
2019 Q1	$434K	Hold	1,942	–	–	﹤0.01%	196
2018 Q4	$361K	Buy	1,942 +754	+63%	+$155K	﹤0.01%	195
2018 Q3	$297K	Hold	1,188	–	–	﹤0.01%	218
2018 Q2	$259K	Sell	1,188 -332	-22%	-$68.4K	﹤0.01%	224
2018 Q1	$291K	Hold	1,520	–	–	﹤0.01%	219
2017 Q4	$238K	Hold	1,520	–	–	﹤0.01%	229
2017 Q3	$236K	Hold	1,520	–	–	﹤0.01%	224
2017 Q2	$245K	Sell	1,520 -1,980	-57%	-$322K	﹤0.01%	220
2017 Q1	$541K	Buy	3,500 +50	+1%	+$6.89K	﹤0.01%	181
2016 Q4	$405K	Sell	3,450 -1,975	-36%	-$225K	﹤0.01%	196
2016 Q3	$612K	Hold	5,425	–	–	﹤0.01%	173
2016 Q2	$504K	Hold	5,425	–	–	﹤0.01%	177
2016 Q1	$425K	Hold	5,425	–	–	﹤0.01%	186
2015 Q4	$396K	Sell	5,425 -425	-7%	-$30.3K	﹤0.01%	193
2015 Q3	$434K	Hold	5,850	–	–	﹤0.01%	187
2015 Q2	$375K	Hold	5,850	–	–	﹤0.01%	198
2015 Q1	$452K	Buy	5,850 +1,138	+24%	+$88.6K	﹤0.01%	183
2014 Q4	$349K	Hold	4,712	–	–	﹤0.01%	202
2014 Q3	$278K	Sell	4,712 -1,138	-19%	-$72K	﹤0.01%	228
2014 Q2	$391K	Buy	+5,850	New	+$372K	﹤0.01%	203

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Fayez Sarofim & Co's IDXX Position: Q2 2026 in Review

Fayez Sarofim & Co reduced its Idexx Laboratories (IDXX) stake by 6.8% in Q2 2026, selling an estimated $84.1K and leaving 2,054 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #182.

Fayez Sarofim & Co first reported a position in IDXX in Q2 2014 and has held it in 49 quarters since. The position peaked at $1.63M in Q4 2025. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Fayez Sarofim & Co held 2,054 shares of Idexx Laboratories worth $1.08M as of Q2 2026.
Fayez Sarofim & Co sold 150 Idexx Laboratories shares in Q2 2026, an estimated $84.1K.
Idexx Laboratories made up ﹤0.01% of Fayez Sarofim & Co's portfolio in Q2 2026, its #182 holding.
Fayez Sarofim & Co first reported a position in Idexx Laboratories in Q2 2014 and has held it in 49 quarters since.
Fayez Sarofim & Co's Idexx Laboratories position peaked at $1.63M in Q4 2025.
1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Fayez Sarofim & Co's 13F filing for Q2 2026, filed 17 Aug 2026.